Human insulin refers to synthetic insulin manufactured in laboratories by growing insulin protein with the help of E. coli bacteria.
Human insulin can be administered orally or through insulin infusion devices. Some common insulin infusion devices are syringes, injection pens, and insulin pumps. These devices are used to deliver insulin on time and on a regular basis.
It has several applications such as the manufacture of monoclonal antibodies, virus vaccines, gene therapy products, and biological drugs. Human insulin is derived from recombinant DNA. Regular and NPH are two common forms of human insulin.
Increasing prevalence of diabetes, increasing obesity endemic, increasing geriatric population, increasing awareness among people about diabetic care and technological advancement in delivery devices of insulin are some of the factors influencing the growth of the human insulin market. However, strict regulatory requirements for approval of insulin and high cost of insulin analog inhibit the growth of the human insulin market.
The increase in the usage of insulin pen for the administration of human insulin is the major trend for the human insulin market. Insulin pens are pen shaped self-injection device, including an insulin cartilage or reservoir for insulin, needle and a dial. It is used to inject the accurate dose of insulin at a time. These are usually injected in thigh, abdomen or arms. The two types of pens are disposable and reusable; disposable pens are preloaded and disposed off once the insulin is used, whereas in reusable pens an empty vial is replaced by new cartilage. Some of the advantages of insulin pen are easy to use, repeatedly accurate dosage and less injection pain. However, it cannot mix different insulin types together in prescribed dose.Technological advancements in insulin delivery devices have attracted various players to invest in the insulin delivery devices market. Companies such as Novo Nordisk A/S, Eli Lilly and Company, and Sanofi are engaged in the manufacturing of insulin pens for the effective management of diabetes in people.
The key players in the human insulin market include Sanofi, Novo Nordisk A/S, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer, Inc., Merck & Co., and Julphar.
